中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2014年
11期
1191-1193
,共3页
王春玲%何正梅%周立涛%史玉叶%陈月%张丽娟%宋立孝%丁邦和%刘定胜
王春玲%何正梅%週立濤%史玉葉%陳月%張麗娟%宋立孝%丁邦和%劉定勝
왕춘령%하정매%주립도%사옥협%진월%장려연%송립효%정방화%류정성
多发性骨髓瘤%地塞米松%药物疗法,联合
多髮性骨髓瘤%地塞米鬆%藥物療法,聯閤
다발성골수류%지새미송%약물요법,연합
Multiple myeloma%Dexamethasone%Drug therapy,combination
目的 观察小剂量雷利度胺联合地塞米松治疗老年人难治复发性多发性骨髓瘤的疗效及安全性. 方法 复发难治性多发性骨髓瘤患者26例,中位年龄66岁,采用小剂量雷利度胺联合地塞米松治疗.雷利度胺10 mg/d,口服,第1～～21天;地塞米松40 mg/d,分2次口服,第1～4天、第9～12天、第17～20天.每28 d为1个周期,每例患者接受2～8个疗程的治疗. 结果 2个疗程后完全缓解(CR)为11.5％ (3/26);非常好的部分缓解(PR)为26.9％(7/26),PR为34.6％ (9/26),总反应率为73.1％ (19/26);随访24个月,19例有反应患者,持续CR 3例,疾病稳定3例,疾病进展13例,中位至疾病进展时间为13个月;7例无反应患者,改用其他方案,疾病稳定2例,疾病进展5例.不良反应主要为乏力、胃肠道反应、周围神经炎、血细胞减少等,但均较轻微. 结论 小剂量雷利度胺联合地塞米松对于老年复发难治性多发性骨髓瘤,是一种安全有效的治疗方法.
目的 觀察小劑量雷利度胺聯閤地塞米鬆治療老年人難治複髮性多髮性骨髓瘤的療效及安全性. 方法 複髮難治性多髮性骨髓瘤患者26例,中位年齡66歲,採用小劑量雷利度胺聯閤地塞米鬆治療.雷利度胺10 mg/d,口服,第1～～21天;地塞米鬆40 mg/d,分2次口服,第1～4天、第9～12天、第17～20天.每28 d為1箇週期,每例患者接受2～8箇療程的治療. 結果 2箇療程後完全緩解(CR)為11.5％ (3/26);非常好的部分緩解(PR)為26.9％(7/26),PR為34.6％ (9/26),總反應率為73.1％ (19/26);隨訪24箇月,19例有反應患者,持續CR 3例,疾病穩定3例,疾病進展13例,中位至疾病進展時間為13箇月;7例無反應患者,改用其他方案,疾病穩定2例,疾病進展5例.不良反應主要為乏力、胃腸道反應、週圍神經炎、血細胞減少等,但均較輕微. 結論 小劑量雷利度胺聯閤地塞米鬆對于老年複髮難治性多髮性骨髓瘤,是一種安全有效的治療方法.
목적 관찰소제량뢰리도알연합지새미송치료노년인난치복발성다발성골수류적료효급안전성. 방법 복발난치성다발성골수류환자26례,중위년령66세,채용소제량뢰리도알연합지새미송치료.뢰리도알10 mg/d,구복,제1～～21천;지새미송40 mg/d,분2차구복,제1～4천、제9～12천、제17～20천.매28 d위1개주기,매례환자접수2～8개료정적치료. 결과 2개료정후완전완해(CR)위11.5％ (3/26);비상호적부분완해(PR)위26.9％(7/26),PR위34.6％ (9/26),총반응솔위73.1％ (19/26);수방24개월,19례유반응환자,지속CR 3례,질병은정3례,질병진전13례,중위지질병진전시간위13개월;7례무반응환자,개용기타방안,질병은정2례,질병진전5례.불량반응주요위핍력、위장도반응、주위신경염、혈세포감소등,단균교경미. 결론 소제량뢰리도알연합지새미송대우노년복발난치성다발성골수류,시일충안전유효적치료방법.
Objective To evaluate the efficacy and safety of low-dose Lenalidomide in combination with Dexamethasone on refractory or relapsed multiple myeloma (MM) in the elderly.Methods 26 patients with refractory or relapsed multiple myeloma who received low-dose Lenalidomide (LD-R) in combination with Dexamethasone(D) were enrolled in this study.The median age of patients was 66 years.Each patient received 10 mg Lenalidomide on days 1 to 21 and 40 mg oral Dexamethasone on days 1 to 4,9 to 12,and 17 to 20 of a 28-day cycle for two to eight cycles.Results The rate of complete response (CR) to Lenalidomide plus Dexamethasone was 11.5％ (3/ 26),the rate of very good partial response (VGPR) was 26.9％ (7/26),the rate of partial response (PR) was 34.6 ％ (9/26),and the overall response rate (ORR) was 73.1％ (19/26) after two cycles.3 cases maintained remission,3 patients had stable disease (SD),and 13 patients had progress disease (PD) in a follow-up period of 24 weeks.The median time to progression was 13 months.Two of the other 7 patients who showed no response had SD and 5 patients had PD when the treatments were changed.Main adverse events were fatigue,gastrointestinal side effects,peripheral neuritis and thrombocytopenia etc,but all events were slight.Conclusions Low-dose Lenalidomide plus Dexamethasone is a safe and effective treatment for the elderly patients with refractory or relapsed multiple myeloma.
